-
促甲状腺激素受体(thyroid-stimulating hormone receptor, TSHR)基因在1989年被克隆出来,它位于染色体14q32,长约60 kb,有10个外显子和9个内含子[1-2]。TSHR蛋白共由764个氨基酸残基组成,分为膜外区、跨膜区和膜内区3个部分。第1-9号外显子编码TSHR蛋白氮端的膜外区,第10号外显子编码跨膜区和膜内区。其中,膜外区有418个氨基酸残基,呈亲水性,是与促甲状腺激素(thyroid-stimulating hormone, TSH)结合的重要部位;跨膜区有264个氨基酸残基,呈疏水性,有7个跨膜段,TSHR蛋白的跨膜区对信息传递、维持TSHR蛋白的三维结构及其生物活性均有影响;而膜内区则与G蛋白耦联来启动信号传导[2-3]。
促甲状腺激素受体与甲状腺癌关系的研究进展
Progress in the relationship of thyroid-stimulating hormone receptor and thyroid carcinoma
-
摘要: 甲状腺癌的预后一般较好,但在核素治疗过程中会有30%的患者发生失分化,失分化甲状腺癌由于不能有效摄取131I而缺少有效的治疗手段,其10年生存率可降至30%~40%。近年来的研究表明:促甲状腺激素受体(TSHR)基因与甲状腺癌的恶性表型有关,分化型甲状腺癌中TSHR基因表达降低,失分化甲状腺癌中TSHR基因表达沉默;体外实验将TSHR基因转染入甲状腺癌细胞株中,在促甲状腺激素刺激下可促进摄碘基因的表达并提高甲状腺癌细胞的摄碘率。由此可知,TSHR基因对于甲状腺癌的发生发展及核素治疗有重要意义。该文回顾了TSHR的基因、蛋白结构以及其在正常甲状腺组织中的作用,对TSHR在甲状腺癌发生发展中的作用及参与的信号传导等方面进行了叙述,对TSHR基因沉默在失分化甲状腺癌中的作用进行了分析。Abstract: Prognosis of thyroid cancer is generally more optimistic, however many tumors (30%) will de-differentiate and become refractory to radioactive iodine, the rate of 10 year survival will be reduced to 30%-40%. Recent data have shown that silencing of thyroid-stimulating hormone receptor (TSHR) appears to be related to the most aggressive behavior of thyroid cancer, TSHR expression is reduced in differentiated thyroid cancer while is lack in de-differentiated thyroid cancer; in vitro experiments, human TSHR gene transfection in thyroid carcinoma cell line can promote the rate of iodine uptake and the expression of the gene of iodine uptake. From this it is clear that TSHR plays an important role in the onset and the development of thyroid cancer. This article briefly reviewed the TSHR gene and protein, the role of TSHR in thyrocyte and the onset of the thyroid cancer, the signaling pathways that TSHR participate in, and analyzed the role of TSHR in de-differentiated thyroid cancer.
-
Key words:
- Thyroid neoplasms /
- Receptors, thyrotropin /
- Gene silencing /
- MAP kinase signaling system
-
[1] 段薇, 杜建玲, 李昌臣. TSHR与自身免疫性甲状腺疾病关系的研究进展.国外医学内分泌学分册, 2003, 23(1): 40-42.
[2] Tomer Y, Barbesino G, Keddache M, et al. Mapping of a major susceptibility locus for Graves' disease (GD-1) to chromosome 14q31. J Clin Endocrinol Metab, 1997, 82(5): 1645-1648. [3] Akamizu T, Moriyama K, Miura M, et al. Characterization of recombinant monoclonal antithyrotropin receptor antibodies(TSHRAbs)derived from lymphocytes of patients with Graves' disease: epitope and binding study of two stimulatory TSHRAbs. Endocrinology, 1999, 140(4): 1594-1601. [4] Marians RC, Ng L, Blair HC, et al. Defining thyrotropin-dependent and -independent steps of thyroid hormone synthesis by using thyrotropin receptor-null mice. Proc Natl Acad Sci USA, 2002, 99(24): 15776-15781. doi: 10.1073/pnas.242322099 [5] García-Jiménez C, Santisteban P. TSH signalling and cancer. Arq Bras Endocrinol Metabol, 2007, 51(5): 654-671. doi: 10.1590/S0004-27302007000500003 [6] Hoffmann S, Maschuw K, Hassan I, et al. Functional thyrotropin receptor attenuates malignant phenotype of follicular thyroid cancer cells. Endocrine, 2006, 30(1): 129-138. [7] 刘翔, 高明.促甲状腺素抗氧化传导通路与甲状腺乳头状癌侵袭力的关系.中华耳鼻咽喉头颈外科杂志, 2009, 44(4): 287-291. doi: 10.3760/cma.j.issn.1673-0860.2009.04.006
[8] Rivas M, Santisteban P. TSH-activated signaling pathways in thyroid tumorigenesis. Mol Cell Endocrinol, 2003, 213(1): 31-45. [9] Xing M, Usadel H, Cohen Y, et al. Methylation of the thyroid-stimulating hormone receptor gene in epithelial thyroid tumors: a marker of malignancy and a cause of gene silencing. Cancer Res, 2003, 63(9): 2316-2321. [10] Yokomori N, Tawata M, Saito T, et al. Regulation of the rat thyrotropin receptor gene by the methylation-sensitive transcription factor GA-binding protein. Mol Endocrinol, 1998, 12(8): 1241-1249. doi: 10.1210/mend.12.8.0142 [11] Roger PP, van Staveren WC, Coulonval K, et al. Signal transduction in the human thyrocyte and its perversion in thyroid tumors. Mol Cell Endocrinol, 2010, 321(1): 3-19. [12] Rivas M, Santisteban P. TSH-activated signaling pathways in thyroid tumorigenesis. Mol Cell Endocrinol, 2003, 213(1): 31-45. [13] Derwahl M, Kuemmel M, Goretzki P, et al. Expression of the human TSH receptor in a human thyroid carcinoma cell line that lacks an endogenous TSH receptor: growth inhibition by cAMP. Biochem Biophys Res Commun, 1993, 191(3): 1131-1138. [14] Shirokawa JM, Elisei R, Knauf JA, et al. Conditional apoptosis induced by oncogenic ras in thyroid cells. Mol Endocrinol, 2000, 14(11): 1725-1738. doi: 10.1210/mend.14.11.0559 [15] Dumaz N, Marais R. Integrating signals between cAMP and the RAS/RAF/MEK/ERK signalling pathways. Based on the anniversary prize of the Gesellschaft für Biochemie und Molekularbiologie Lecture delivered on 5 July 2003 at the Special FEBS Meeting in Brussels. FEBS J, 2005, 272(14): 3491-3504. doi: 10.1111/j.1742-4658.2005.04763.x [16] De Gregorio G, Coppa A, Cosentino C, et al. The p85 regulatory subunit of PI3K mediates TSH-cAMP-PKA growth and survival signals. Oncogene, 2007, 26(14): 2039-2047. doi: 10.1038/sj.onc.1210011 [17] Simon D, Körber C, Krausch M, et al. Clinical impact of retinoids in redifferentiation therapy of advanced thyroid cancer: final results of a pilot study. Eur J Nucl Med Mol Imaging, 2002, 29(6): 775-782. doi: 10.1007/s00259-001-0737-6 [18] 侯莎莎, 王辉, 冯方, 等.重组质粒hTSHR转染低分化甲状腺癌细胞株后对摄碘能力及特异性基因表达的影响.中华核医学杂志, 2011, 31(2): 92-96. doi: 10.3760/cma.j.issn.0253-9780.2011.02.005
[19] Paron I, D'Ambrosio C, Scaloni A, et al. A differential proteomic approach to identify proteins associated with thyroid cell transformation. J Mol Endocrinol, 2005, 34(1): 199-207. doi: 10.1677/jme.1.01618 [20] Kim HJ, Chae HZ, Kim YJ, et al. Preferential elevation of Prx I and Trx expression in lung cancer cells following hypoxia and in human lung cancer tissues. Cell Biol Toxicol, 2003, 19(5): 285-298. doi: 10.1023/B:CBTO.0000004952.07979.3d [21] Park JH, Kim YS, Lee HL, et al. Expression of peroxiredoxin and thioredoxin in human lung cancer and paired normal lung. Respirology, 2006, 11(3): 269-275. doi: 10.1111/j.1440-1843.2006.00849.x
计量
- 文章访问数: 2622
- HTML全文浏览量: 1308
- PDF下载量: 2